nature medicine a r t i c l e s High plasma lipid concentrations are a risk factor for various cardiovascular and metabolic disorders such as atherosclerosis, obesity and metabolic syndrome. Cardiovascular disease is the leading cause of death in the United States 1 . Statins reduce the incidence of coronary artery disease by 20-40% in treated individuals, highlighting a need for new approaches for lowering plasma lipid concentrations 2 . Dietary and endogenous lipids are transported in plasma by lipoproteins made mainly by enterocytes and hepatocytes 3, 4 . MTP assists in lipoprotein assembly by interacting with and lipidating nascent APOB to form precursors of low-density lipoprotein [5] [6] [7] [8] . Therefore, MTP has been targeted to lower plasma lipid concentrations. However, these attempts have been hindered because MTP inhibitors cause steatosis and increase plasma transaminase concentrations, in particular those of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) [9] [10] [11] [12] . Recent studies have highlighted the importance of miRNAs in the regulation of gene expression. miRNAs interact with the 3′ untranslated region (3′ UTR) of target mRNAs and reduce protein synthesis by enhancing mRNA degradation, interfering with mRNA translation or both 13, 14 . The role of miRNAs in lipoprotein assembly and in regulating plasma APOB-containing lipoprotein concentrations has not been previously studied.
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RESULTS miR-30c reduces MTP activity and medium APOB concentrations Using the TargetScan algorithm based on seed recognition, we identified several miRNAs that could potentially interact with the MTP transcript ( Supplementary Fig. 1a) . However, only the miR-30 family was evolutionarily conserved among vertebrates (Supplementary Fig. 1a ). To test whether the miR-30 family regulates MTP, we introduced different family members into human hepatoma Huh-7 cells. Whereas expression of miR-30b or miR-30e had no effect, expression of miR-30c significantly reduced (~50%) MTP activity as compared to a control scramble (scr) miRNA (Fig. 1a) . Moreover, whereas expression of anti-miR-30b or anti-miR-30e had no effect, expression of anti-miR-30c increased MTP activity (Fig. 1a) , suggesting that endogenous miR-30c regulates MTP expression. Furthermore, expression of miR-30c and anti-miR-30c reduced and increased, respectively, MTP protein amounts (Fig. 1b) . Because MTP is crucial for the assembly of APOB-containing lipoproteins, we studied the effect of miR-30c on APOB. As expected, transfection with miR-30c increased miR-30c concentrations (Fig. 1c) . miR-30c reduced and anti-miR-30c increased the concentrations of APOB in the culture medium (Fig. 1d) ; neither miR-30c nor anti-miR-30c had an effect on APOAI concentrations in the culture medium (Fig. 1d) . Moreover, expression of miR-30b or miR-30e had no effect on APOB concentrations in the culture medium (Fig. 1e) . These results indicate that miR-30c overexpression reduces the amount of MTP in cells and of APOB in the culture medium. The finding that miR-30e does not affect MTP activity is consistent with its lack of base pairing interactions with MTP mRNA beyond the seed sequence (Supplementary Fig. 2 ). The finding that miR-30b also has no effect suggests that more than five base pairs are needed at the supplementary site for miR-30 family members, such as miR-30c, to reduce MTP expression.
To determine whether miR-30c affects APOB synthesis or secretion, we performed pulse-labeling studies in Huh-7 cells. Neither APOB nor albumin synthesis were affected by expressing miR-30c or anti-miR-30c as compared to scr miRNA (Fig. 1f) . Pulse-chase studies revealed that the intracellular disappearance of APOB and albumin over time was unaffected by expressing miR-30c or anti-miR-30c (Fig. 1g) . The amount of albumin in the culture medium was also unaffected. However, secretion of APOB was lower and higher in cells transfected with miR-30c and anti-miR-30c, respectively, compared with those transfected with scr miRNA. These results indicate that miR-30c does not affect synthesis but reduces secretion of APOB.
miR-30c interacts with 3′ UTR of MTP and reduces mRNA levels To understand how miR-30c regulates MTP expression and activity, we measured its effects on MTP mRNA levels. Expression of increasing amounts of miR-30c decreased MTP mRNA levels by 60-70%, whereas the highest amount of anti-miR-30c tested increased MTP mRNA levels (Fig. 2a) . To explain how miR-30c reduces MTP mRNA levels, we treated transfected cells with actinomycin D to inhibit transcription. After treatment, MTP mRNA disappeared faster from cells expressing miR-30c than those expressing scr miRNA, indicating an effect on MTP mRNA degradation (Fig. 2b) . We did not study the effect of miR-30c on MTP mRNA translation. Values in each treatment group (scr miRNA, miR-30c and anti-miR-30c) were normalized to those at time 0, which was set to 100% (n = 3 replicates per group). The data are representative of two experiments. *P < 0.05, **P < 0.01, ***P < 0.001 determined by one-way analysis of variance (ANOVA) compared with scr miRNA. All data are shown as the mean ± s.d.
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We further evaluated how miR-30c affects MTP mRNA levels in COS-7 cells, which are deficient in MTP expression. MTP activity and mRNA levels were reduced when MTP expression plasmids containing the 3′ UTR were co-transfected with miR-30c, as compared to scr miRNA (Fig. 2c) . In contrast, anti-miR-30c increased MTP expression (Fig. 2c) . We next studied the importance of the miR30c target seed sequence located 90-94 bases after the MTP stop codon (Supplementary Fig. 1b) . First, mutagenesis of this sequence abolished the effects of miR-30c and anti-miR-30c on MTP activity (Fig. 2d) . Second, luciferase activity of the psiCHECK2 plasmid encoding a luciferase gene fused with the MTP 3′ UTR was decreased and increased in the presence of miR-30c and anti-miR-30c, respectively, and these effects were abolished when the miR-30c binding site was mutated (Fig. 2e) . Third, when coexpressed with a plasmid encoding Flag-tagged human MTP (Flag-hMTP) lacking the 3′ UTR, neither miR-30c nor anti-miR-30c had an effect on MTP activity or mRNA levels (Fig. 2f) . These results suggest that miR-30c binds to the 3′ UTR of MTP mRNA and induces mRNA degradation.
Tissue expression of miR-30c
We measured steady-state levels of miR-30c in human tissues and found high expression in the heart, skeletal muscle and kidney (Fig. 2g) . We detected comparatively lower but still substantial amounts of miR-30c in other tissues (Fig. 2g) . In contrast, we found high levels of MTP mRNA in the small intestine and liver (Fig. 2h) . miR-30c is conserved in vertebrates (Supplementary Fig. 3 ) and resides in intron 5 of the human nuclear transcription factor Y subunit C (NFY-C) gene. We found NFY-C to be ubiquitously (g) miR-30c, miR-30b and miR-30e levels in human tissues assessed by quantitative RT-PCR (qRT-PCR) and normalized to SNORD44 levels. The value in one sample of kidney and spleen was adjusted to 1. The data are representative of two experiments. Skel., skeletal; int., intestine. (h,i) MTP, pri-miR-30c and NFY-C mRNA levels in human tissues assessed by qRT-PCR and normalized to ARPp0 levels. The MTP levels in spleen (h) and the pri-miR-30c and NFY-C values in liver (i) were adjusted to 1. The data are representative of two experiments. (j) DICER mRNA, pri-miR-30c, miR-30c, MTP mRNA and NFY-C mRNA levels in Huh-7 cells transfected with 20 nM siDICER. Values are shown relative to the levels of ARPp0 and U6 for mRNAs and miRNAs, respectively. The data are representative of two experiments. *P < 0.05, **P < 0.01, ***P < 0.001 compared to scr miRNA and determined by one-way ANOVA; @@ P < 0.01, @@@ P < 0.001 determined by Student's t test. All data are shown as the mean ± s.d. npg a r t i c l e s nature medicine VOLUME 19 | NUMBER 7 | JULY 2013expressed, with high expression levels in the human heart and testes (Fig. 2i ). This expression pattern was different from that of miR-30c ( Fig. 2g) but was similar to that of pri-miR-30c (Fig. 2i) , suggesting that pri-miR-30c is transcribed as part of the primary NFY-C mRNA and that miR-30c levels are regulated posttranscriptionally. To test this idea further, we reduced the expression of DICER, which is crucial for miRNA biogenesis 13, 15 . Treatment of Huh-7 cells with DICER-specific siRNA (siDICER) reduced DICER mRNA levels by 90%, had no effect on pri-miR-30c levels or NFY-C mRNA, reduced miR-30c levels and increased MTP mRNA levels (Fig. 2j) . We interpret these data as indicating that pri-miR-30c is transcribed as part of NFY-C mRNA and that miR-30c levels and NFY-C mRNA concentrations diverge because of differences in their post-transcriptional processing.
miR-30c lowers plasma cholesterol concentrations
We next explored the physiological consequences of hepatic overexpression of miR-30c. We transduced male C57BL/6 mice with miRNA-expressing lentivirus and fed them a Western diet ad libitum. After 3 weeks, hepatic miR-30c levels were approximately fourfold higher in miR-30c-expressing mice, with no effects on endogenous miR-30b and miR-30e levels (Fig. 3a) . miR-30c levels did not increase in other tissues (Supplementary Fig. 4a) . Expression of miR-30c and anti-miR-30c reduced and increased, respectively, hepatic MTP mRNA levels, activity and protein amounts (Fig. 3b) , with no effects in other tissues (Supplementary Fig. 4b) . Furthermore, miR-30c had no effect on ApoB (Supplementary Fig. 4d ), ApoA1 ( Supplementary  Fig. 4e), Abca1 (Supplementary Fig. 4f ) or Abcg1 ( Supplementary  Fig. 4g ) transcripts in the tissues tested. These studies indicate that The slopes between 1 h and 2 h were used to calculate triglyceride production rates. The data are from one experiment. (f) Hepatic triglyceride and cholesterol concentrations in the mice described in a and b at 3 weeks after lentivirus injection. (g,h) β-oxidation (g), triglyceride and phospholipid synthesis (h) in liver slices of the mice described in a and b at 3 weeks after lentivirus injection. The data (a-d,f-h) are representative of three experiments. c.p.m., counts per minute. *P < 0.05, **P < 0.01, ***P < .001 determined by one-way ANOVA; # P < 0.05, ## P < 0.01, ### P < 0.001, #### P < 0.0001 determined by two-way ANOVA compared with scr miRNA. All data are shown as the mean ± s.d. npg a r t i c l e s lentiviral delivery of miR-30c led to its expression mainly in the liver and reduced hepatic MTP expression and activity. miR-30c significantly reduced (16-27%), whereas anti-miR-30c significantly increased (20-54%), plasma cholesterol concentrations as a result of changes in non-high-density lipoprotein (HDL) ApoBcontaining lipoproteins (Fig. 3c) . However, miR-30c and anti-miR-30c had no effect on fasting triglyceride (Fig. 3d), AST (Supplementary  Fig. 4h) or ALT (Supplementary Fig. 4i) concentrations. These studies indicate that miR-30c reduces plasma cholesterol concentrations because of decreases in non-HDL lipoprotein concentrations without increasing plasma transaminase concentrations.
We hypothesized that lower plasma lipid concentrations in Western diet-fed mice overexpressing miR-30c might be due to reduced hepatic lipoprotein production. In mice injected with poloxamer 407 to inhibit lipases 16 , hepatic triglyceride production rates were significantly higher in mice expressing anti-miR-30c (372 mg dl −1 h −1 ) and were lower in mice expressing miR-30c (119 mg dl −1 h −1 ) as compared to mice expressing scr miRNA (205 mg dl −1 h −1 ; Fig. 3e) . Therefore, hepatic overexpression of miR-30c reduces the production of triglyceride-rich lipoproteins.
miR-30c lowers hepatic lipid synthesis The studies described above showed that miR-30c reduces hepatic lipoprotein production and plasma cholesterol concentrations.
We next measured lipid concentrations in liver homogenates of mice overexpressing miR-30c, expecting an increase in their concentrations. However, hepatic triglyceride and cholesterol concentrations were not increased in these mice (Fig. 3f) . To understand why miR-30c did not increase hepatic lipid concentrations, we studied hepatic β-oxidation, de novo lipogenesis and triglyceride and phospholipid biosynthesis. Expression of miR-30c or anti-miR-30c had no effect on β-oxidation (Fig. 3g) ; however miR-30c and anti-miR-30c expression reduced and increased, respectively, the synthesis of fatty acids, phospholipids and triglycerides (Fig. 3h) . These studies demonstrate that miR-30c reduces hepatic lipid synthesis.
To study the mechanisms by which miR-30c affects lipid synthesis, we performed Gene Ontology analysis to identify potential miR-30c target genes. This analysis revealed that miR-30c could potentially affect several lipid synthesis pathways (Supplementary Fig. 5a ) and genes ( Supplementary Fig. 5b ). We selected one gene from each pathway for further study. Hepatic miR-30c overexpression reduced lysophosphatidylglycerol acyltransferase 1 (Lpgat1), Elovl5, Stard3 and membrane bound O-acyltransferase domain containing 1 (Mboat1) hepatic mRNA levels (Fig. 4a) . Expression of miR-30c in Huh-7 cells reduced the mRNA levels of these genes, whereas expression of anti-miR-30c increased their levels (Fig. 4b) . To ascertain their roles in lipid synthesis, we reduced (by ~80-90%) the expression of individual genes using specific siRNAs (Fig. 4c) . Knockdown of these Values are shown relative to the scr miRNA or siGL2 group, which was set to 100%. The data are representative of two experiments. *P < 0.05, **P < 0.01, ***P < 0.001 compared to the scr miRNA-expressing or siGL2-expressing control group determined by one-way ANOVA; # P < 0.05, ## P < 0.01, ### P < 0.001, #### P < 0.0001 for the scr miRNA-expressing or siGL2-expressing group compared to the miR-30c-expressing group determined by two-way ANOVA. All data are shown as the mean ± s.d. genes had no effect on MTP activity (Fig. 4d) or culture medium APOB or APOAI concentrations (Fig. 4e,f) , suggesting that they do not have a role in lipoprotein secretion. In contrast, MTP knockdown reduced MTP mRNA levels (Fig. 4c) , MTP activity ( Fig. 4d) and culture medium APOB concentrations ( Fig. 4e) but had no effect on culture medium APOAI concentrations (Fig. 4f) . We next determined the effects of reducing the expression of these genes on lipid synthesis. Knockdown of MTP, MBOAT1 or STARD3 had no effect, but knockdown of ELOVL5 or LPGAT1 reduced de novo lipogenesis (Fig. 4g) . To evaluate whether these genes are targeted by miR-30c, we co-transfected cells with siRNAs along with either scr miRNA or miR-30c. miR-30c reduced lipid synthesis in control cells and in cells treated with siRNA constructs targeting MTP, MBOAT1, ELOVL5 or STARD3 but not in cells treated with an siRNA construct targeting LPGAT1 (Fig. 4h) . This result suggests that LPGAT1 has a role in lipid synthesis and is targeted by miR-30c.
To determine whether reduced expression of LPGAT1 would affect culture medium APOB concentrations, we transfected Huh-7 cells with siRNAs and either scr miRNA or miR-30c (Fig. 4i) . Knockdown of LPGAT1 had no effect on APOB concentrations, whereas knockdown of MTP significantly reduced APOB concentrations. miR-30c reduced APOB concentrations in cells treated with each of the siRNAs tested except for those treated with siRNA targeting MTP. These studies suggest that miR-30c reduces hepatic lipid synthesis and APOB secretion by targeting LPGAT1 and MTP, respectively.
These cell culture studies indicated that miR-30c reduces lipid synthesis independently of MTP. To test this in vivo, we transduced liver-specific MTP-deficient mice (albumin (Alb)-Cre;Mttp flox/flox , called here L-Mttp −/− ) with lentivirus expressing miR-30c. A threefold increase in hepatic miR-30c levels had no effect on the expression of miR-30b or miR-30e (Fig. 5a) or the concentrations of plasma triglyceride (Fig. 5b), cholesterol (Fig. 5c) or hepatic cholesterol (Fig. 5d) . However, miR-30c-expressing livers had lower hepatic triglyceride concentrations (Fig. 5e) . miR-30c had no effect on fatty acid oxidation but reduced fatty acid and triglyceride concentrations and phospholipid synthesis (Fig. 5f-i) . In a separate experiment, hepatic miR-30c or anti-miR-30c expression in L-Mttp −/− mice had no effect on plasma triglyceride or cholesterol concentrations ( Supplementary  Fig. 6a ) in either HDL or non-HDL lipoproteins ( Supplementary  Fig. 6b ) as compared to scr miRNA. However, the concentration of hepatic triglycerides, but not cholesterol, was reduced in mice with hepatic miR-30c expression (Supplementary Fig. 6c) . As a control, we performed similar experiments in Mttp flox/flox mice. Threefold overexpression of miR-30c ( Supplementary Fig. 7a ) had no effect on the concentrations of plasma triglycerides (Supplementary Fig. 7b) , hepatic cholesterol or hepatic triglycerides (Supplementary Fig. 7c ) or on fatty acid oxidation (Supplementary Fig. 7d ). However, miR-30c overexpression did reduce plasma cholesterol concentrations (Supplementary Fig. 7b ) and hepatic lipid synthesis ( Supplementary  Fig. 7e ). These data indicate that miR-30c reduces hepatic triglyceride concentrations through targets other than MTP.
miR-30c reduces atherosclerosis
In view of our findings that overexpression of miR-30c decreases de novo hepatic lipogenesis, reduces MTP activity and lowers plasma lipid concentrations in Western diet-fed wild-type mice, we evaluated the effects of miR-30c on atherosclerosis. In female Apoe −/− mice fed a Western diet, transduction with miR-30c-expressing lentivirus led to significant reductions in plasma cholesterol (Fig. 6a) and triglyceride (Fig. 6b) concentrations as compared to transduction with scr miRNA-expressing lentivirus. In contrast, plasma lipid concentrations were generally higher in anti-miR-30c-expressing mice as compared to scr miRNA-expressing mice (Fig. 6a,b) . We found similar reductions in plasma lipid concentrations in miR-30c-expressing mice in a separate experiment (Supplementary Fig. 8a) . However, plasma AST and ALT activities were not significantly different between the scr miRNA-expressing and miR-30c-expressing groups (Supplementary Fig. 8a ). Triglyceride secretion rates were higher and lower in the anti-miR-30c-expressing and miR-30c-expressing groups, respectively, compared with the control group expressing scr miRNA (Fig. 6c) . Plasma ApoB100 and ApoB48 concentrations (Fig. 6d,e) were significantly lower and higher in miR-30c-expressing and anti-miR-30c-expressing mice, respectively, compared with mice expressing scr miRNA. These data indicate that miR-30c reduces the production of triglyceride-rich ApoB-containing lipoproteins.
Visual inspection of aortic arches showed fewer and more atherosclerotic plaques in miR-30c-expressing and anti-miR-30c-expressing mice, respectively, compared with scr miRNA-expressing mice ( Fig. 6f and Supplementary Fig. 8b ). H&E staining of the cardiac-aortic junctions revealed that plaques were smaller in the miR-30c-expressing group than in the groups expressing scr miRNA or anti-miR-30c (Fig. 6g and Supplementary Fig. 8c ). 
npg a r t i c l e s
Macrophage staining at the cardiac-aortic junctions was higher in the anti-miR-30c-expressing group and lower in miR-30c-expressing group compared to the scr miRNA-expressing group ( Fig. 6h and Supplementary Fig. 8d ). Oil Red O staining of whole aortas revealed a significantly reduced lesion area in miR-30c-expressing mice compared with scr miRNA-expressing mice (Fig. 6i,j and Supplementary  Fig. 8e,f) . These studies indicate that miR-30c reduces atherosclerosis in Apoe −/− mice.
DISCUSSION
We identified MTP as a target of miR-30c and showed that miR-30c binding to the 3′ UTR of MTP mRNA causes faster degradation of the mRNA. Hepatic overexpression of miR-30c reduces MTP mRNA levels, protein amounts and activity. miR-30c lowers plasma cholesterol concentrations by reducing the production of triglyceride-rich ApoB-containing lipoproteins, an effect that is probably secondary to lower MTP expression. miR-30c also reduces de novo lipogenesis, possibly by targeting genes involved in lipid biosynthesis such as the LPGAT1 gene. Additionally, atherosclerotic plaques are smaller in Apoe −/− mice overexpressing miR-30c. These results support a model in which hepatic overexpression of miR-30c reduces both lipoprotein production through inhibition of MTP and lipid synthesis through regulation of other genes; decreased lipid synthesis might explain why miR-30c overexpression does not lead to steatosis, as has been previously observed with MTP inhibition (Supplementary Fig. 9 ).
Although endogenous levels of miR-30c in the liver are low compared to those in the heart, our data indicate that endogenous miR-30c has a role in plasma and liver lipid homeostasis, as overexpression of anti-miR-30c had the opposite effect as compared to overexpression of miR-30c. Furthermore, previous studies have shown that miR-30c expression is modulated by a high-fat diet and genetic perturbations. Hepatic miR-30c levels are 1.3-fold higher in db/db and diet-induced obese mice compared to controls 17 . Moreover, miR-30c levels are higher than those of miR-33 in chow-fed mice, and miR-30c levels are threefold higher than those of miR-33 in Western diet-fed mice 18 . This is an important point, as miR-33 antagomirs markedly reduce hepatic ABCA1 expression, plasma HDL concentrations and atherosclerosis [19] [20] [21] . Thus, there is ample evidence for hepatic expression and regulation of miR-30c, consistent with a role for endogenous miR-30c in lipid homeostasis.
In mice with miR-30c overexpression, the degree to which hepatic MTP protein amounts were decreased was greater than what might have been anticipated on the basis of the more modest effect on mRNA levels. Our studies in Huh-7 cells showed that one mechanism for the effect of miR-30c on MTP mRNA levels involves posttranscriptional mRNA degradation. However, as miRNAs also interfere with protein translation 13, 15 , miR-30c might also interfere with MTP protein translation. This possibility will need to be tested in future studies.
Whereas anti-miR-30c expression in cells only modestly increased MTP protein amounts, it had a greater effect on APOB secretion. It is npg therefore possible that anti-miR-30c affects the expression of additional proteins involved in APOB secretion, which may, for example, affect the post-translational degradation of APOB. Our data suggest that miR-30c lowers plasma and hepatic lipid concentrations by targeting MTP and LPGAT1, respectively. First, in mice with liver-specific deficiency of MTP, miR-30c did not reduce plasma cholesterol concentrations as it did in wild-type mice. Second, in Huh-7 cells, the effect of miR-30c on reducing APOB secretion was blocked by MTP knockdown but not by LPGAT1 knockdown. We used a similar approach in Huh-7 cells to study the involvement of LPGAT1 in lipogenesis. Although LPGAT1 knockdown had no effect on APOB secretion, it reduced fatty acid synthesis, and the effect of miR-30c on reducing lipogenesis was blocked by LPGAT1 knockdown. These studies indicate that MTP and LPGAT1 are required for miR-30c to modulate APOB secretion and hepatic lipogenesis, respectively.
Whereas miR-30c reduced plasma cholesterol concentrations in both wild-type and Apoe −/− mice, it had differing effects on fasting plasma triglyceride concentrations in these mice: miR-30c reduced plasma triglyceride concentrations in Western diet-fed Apoe −/− mice but had no effect in wild-type mice on the same diet. Nevertheless, miR-30c reduced triglyceride production in both wild-type and Apoe −/− mice. These differing effects of miR-30c on plasma triglyceride concentrations are probably related to reduced lipoprotein lipase activity in the absence of ApoE. Consistent with this hypothesis, it has been shown that heparin injection does not affect plasma triglyceride concentration in Apoe −/− mice, unlike in wild-type mice, in which heparin reduces plasma triglyceride concentrations 22 . Purified lipoprotein lipase can completely hydrolyze lipoproteins from wild-type but not from Apoe −/− mice, but hydrolysis of lipoproteins from Apoe −/− mice does occur when lipoprotein lipase is incubated with lower amounts of lipoproteins 22 . On the basis of these observations, the authors concluded that lipoprotein lipase activity is saturated in Apoe −/− mice and is therefore unable to hydrolyze lipoproteins as efficiently as in wild-type mice. A separate study 23 provided a different explanation for the reduced lipoprotein lipase activity in Apoe −/− mice. These authors advanced the idea that endogenous ApoCI is sufficient to inhibit lipoprotein lipase activity in Apoe −/− mice. The lower lipoprotein lipase activity in Apoe −/− as compared to wild-type mice, as observed in both of these studies 22, 23 , might explain why miR-30c reduces plasma triglyceride concentrations in Apoe −/− but not wild-type mice. In wildtype mice, differences in plasma triglyceride concentrations are not obvious, as high lipase activity would hydrolyze all lipoproteins to the maximum extent. In Apoe −/− mice, where lipase activity might be limiting, plasma triglyceride concentrations reflect changes in lipoprotein production.
Despite having the same seed sequence, members of the miR-30 family have been shown to have distinct functions 24, 25 . miR-30a has a role in Xenopus kidney development 26 , miR-30e regulates apoptosis in breast tumor cells 27 , and miR-30a, miR-30c and miR-30d stimulate adipogenesis 28, 29 . Thus, individual members of this miRNA family seem to control different pathways. Additional studies are needed to explain the mechanisms that contribute to the specificity of their actions.
In conclusion, our studies provide evidence that miR-30c reduces MTP expression to reduce APOB-containing lipoprotein secretion and, independently of effects on MTP, reduces lipid synthesis. Hepatic miR-30c overexpression coordinately lowers plasma lipid concentrations and lipid biosynthesis and does not result in steatosis.
Hence, miR-30c mimics might have therapeutic potential as antihyperlipidemic and anti-atherosclerotic agents.
METHODS
Methods and any associated references are available in the online version of the paper. triglycerides, using a kit (Chylos, Inc.) 35, 36 . For reporter assays, cells were washed with cold PBS and incubated with Passive Lysis Buffer (Promega). Cell lysates were then mixed with Luciferase Assay Substrate and Stop & Glo Substrate sequentially (Promega) and luciferase activity was measured in a luminometer. Values obtained from the luciferase activity (Luciferase Assay substrate) and Renilla luciferase activity measurements (Stop & Glo substrate) were used to calculate a ratio. All values were normalized to the scr miRNA group.
Small RNA interference. Huh-7 cells were transfected with siRNAs against target genes or control siRNA (siGL2 (ref. 39)) using the RNAiMAX (Invitrogen) transfection reagent. After 48 h, RNA was extracted and used for qRT-PCR.
Western blot analyses. Tissue and cell samples were homogenized in lowsalt buffer containing 1 mM Tris-Cl, pH 7.6, 1 mM EGTA, 1 mM MgCl 2 and protease inhibitor cocktail (Roche). Proteins (~10 µg) were resolved on SDS-PAGE gels (7.5% for MTP and 5% for ApoB). A monoclonal mouse antibody to mouse MTP (BD Biosciences, product ID 612022), a rabbit antibody to mouse PDI (Santa Cruz, sc-20356), a goat antibody to human GAPDH (Santa Cruz), a goat antibody to human MTP (Santa Cruz, sc-33116) and a goat antibody to human APOB (Texas Academy Biosciences, 20A-G1) were used as the primary antibodies. All antibodies were used at 1:1,000 dilution for western blot analyses. We used Alexa Fluor 633 (Invitrogen) mouse-, rabbitor goat-specific secondary antibodies, and the blots were visualized using a Storm 860 device (Amersham).
Fatty acid oxidation, de novo lipogenesis, and phospholipid and triglyceride synthesis. For fatty acid oxidation measurements, fresh liver slices (30 mg) were incubated with [ 14 C]oleic acid (0.3 µCi) for 2 h, and the radiolabeled CO 2 was captured with a filter paper soaked with phenylethylamine 33 . De novo lipogenesis was assayed by incubating fresh liver slices or Huh-7 cells with [ 14 C]acetate (0.2 µCi). Lipids were extracted after saponification 33, 40, 41 . Phospholipid and triglyceride synthesis were assessed by incubating liver slices with [ 3 H]glycerol (0.5 µCi), extracting lipids and separating them by thin layer chromatography using a Silica-60 plate and a solvent mixture of diethyl ether, benzene, ethanol and acetic acid at a ratio of 50:40:2:0.2 (ref. 42 ). Counts were measured in a scintillation counter (Beckman LS 6000TA).
Aortic plaque analyses. The aortas were dissected, and the arches were photographed. Lipids were visualized on aorta en face with Oil Red O 43 . Quantification of Oil Red O staining was done with ImageJ. Lesion visualization in aortic roots was performed by sectioning and staining with H&E. Macrophages were detected using the sc-101447 antibody (1:1,000, Santa Cruz Biotechnology) 43 .
